Thyroid conditions: what the guidelines say

The thyroid is a small gland in the neck that produces hormones regulating metabolism, energy use, and many other body functions. Thyroid disease means the gland is producing too little hormone (hypothyroidism) or too much (hyperthyroidism), and both patterns become more common from midlife onward, especially in women. This page describes what the American Thyroid Association (ATA), whose guidelines are frequently developed alongside The Endocrine Society and other endocrine societies, says about diagnosing and framing management of both conditions, along with a genuinely unsettled area of the evidence: mild, subclinical thyroid abnormalities.

How TSH testing works, and the typical reference range

The standard first test for thyroid function is thyroid-stimulating hormone (TSH), a hormone produced by the pituitary gland that rises when it detects too little thyroid hormone in the blood, and falls when it detects too much. Because of this feedback relationship, TSH moves in the opposite direction from thyroid hormone levels: a high TSH generally signals an underactive thyroid, and a low TSH generally signals an overactive one. When TSH is abnormal, clinicians typically also check free T4, a direct measure of one of the thyroid hormones circulating in the blood, to confirm the pattern and gauge its severity.

Most labs report a normal TSH reference range of roughly 0.4 to 4.0 mIU/L, though the exact cutoffs vary somewhat between laboratories and testing methods. TSH also tends to drift upward with age: several studies of age-specific reference ranges have found meaningfully higher upper limits in adults over 65 or 70 than the general adult range implies. The ATA and other groups note that applying a single, one-size-fits-all reference range across all ages can lead to over-diagnosing mild thyroid abnormalities in older adults whose modestly elevated TSH may be typical for their age rather than a sign of disease.

Hypothyroidism: what the guideline says about treatment

Hypothyroidism, an underactive thyroid, is most commonly caused by autoimmune thyroiditis (Hashimoto’s disease) in the United States. The ATA’s 2014 guideline on treating hypothyroidism concludes that levothyroxine, a synthetic form of the T4 hormone the thyroid normally produces, should remain the standard therapy, stating that no consistently strong evidence supports alternative approaches, such as combination T4/T3 therapy or desiccated thyroid extract, as superior for most patients. This page names levothyroxine as the guideline’s standard replacement therapy category; it does not state a dose, since the correct replacement amount depends on a person’s weight, age, the severity of their hypothyroidism, and other individual factors that only a clinician assessing lab results over time can determine.

Hyperthyroidism: the option categories the guideline describes

Hyperthyroidism, an overactive thyroid, is most often caused by Graves’ disease, though toxic nodules and other causes exist. The ATA’s 2016 guideline, covering hyperthyroidism and other causes of thyrotoxicosis, describes three main option categories once a cause is identified: antithyroid medications (drugs that reduce the thyroid’s hormone output), radioactive iodine (a treatment that selectively destroys overactive thyroid tissue), and surgery to remove some or all of the thyroid gland. The guideline frames the choice among these as depending on the underlying cause, the severity of the condition, a person’s age and other health conditions, and personal preference, without designating a single universal first choice for every patient. This page names these as categories, not a treatment plan or a dose for any medication.

The honest debate: subclinical hypothyroidism

This is the area of thyroid care where the evidence genuinely does not point in one clear direction, and it is worth describing plainly rather than glossing over. Subclinical hypothyroidism means TSH is mildly elevated, commonly cited in the range of roughly 4.5 to 10 mIU/L, while free T4 remains within its normal range: the pituitary is signaling for more hormone, but the standard direct measure of thyroid hormone has not yet dropped out of range.

When TSH is above 10 mIU/L, guidance is more consistent in favoring treatment, particularly in younger adults, reflecting a higher likelihood of progression to overt hypothyroidism and a clearer signal that something meaningful is happening. Below that threshold, the picture is genuinely mixed. The 2017 TRUST trial, a large randomized, placebo-controlled study led by Stott and colleagues and published in the New England Journal of Medicine, enrolled 737 adults age 65 and older (mean age about 74) with subclinical hypothyroidism (TSH between 4.6 and 19.9 mIU/L with normal free T4) and randomized them to levothyroxine or placebo. After a year of treatment, the trial found no meaningful improvement in hypothyroid symptoms or tiredness scores in the levothyroxine group compared with placebo. This is a directly relevant, well-conducted trial that failed to show the benefit many clinicians had assumed treatment would produce in older adults with mild TSH elevation, and it has meaningfully shaped how guidance discusses this group since.

Because of results like these, current thinking generally favors an individualized approach for TSH under 10: considering treatment more strongly when a person has clear hypothyroid symptoms, is positive for thyroid autoantibodies (a marker of underlying autoimmune thyroiditis and higher likelihood of progression), is younger, or has specific cardiovascular risk considerations, while favoring watchful monitoring, rather than automatic treatment, in older adults with mild, symptom-free TSH elevation. None of this page determines where an individual reader falls in that judgment call; it is exactly the kind of individualized decision the guidelines route to a clinician.

The honest nuances

Two things are true at once here, and both matter. First, thyroid hormone testing is genuinely useful and treatment for clear, overt thyroid disease is well-supported and often produces a meaningful improvement in symptoms. Second, the zone of mildly elevated TSH with normal free T4, a very commonly encountered lab pattern, especially in older adults, is exactly where the evidence is weakest for automatic treatment, and a well-designed, adequately powered trial (TRUST) found no symptom benefit from treating it in older adults. Age-specific TSH reference ranges add a further layer: a TSH that looks “high” against a young adult’s reference range may sit within the expected range for someone in their 70s or 80s, which is part of why a single number, without context on age, symptoms, and antibody status, does not settle the question on its own.

Questions to discuss with your clinician

• What is my TSH, and does my lab report an age-adjusted reference range or a single adult-wide range?
• If my TSH is mildly elevated, where does it fall relative to the 10 mIU/L threshold, and has it been confirmed on a repeat test?
• Am I positive for thyroid autoantibodies, and does that change how this result should be interpreted?
• Given the TRUST trial’s findings, what specific benefit would treatment be expected to provide in my situation?
• If I have overt hypothyroidism or hyperthyroidism, which option category is being considered for me, and why that one over the alternatives?
• How often should my thyroid function be rechecked to see whether the current approach, including watchful monitoring, is appropriate?

For related evidence on symptoms that can overlap with thyroid changes, see the companion profile on menopause, and for broader midlife metabolic context, see prediabetes and type 2 diabetes.